The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Voskanyan S.Ae.

State scientific center, Federal medical biophysical center named after A.I. Burnasyan, Federal medico-biological agency, Moscow, Russia

Sushkov A.I.

State Research Center — Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency of Russia, Moscow, Russia

Artem'ev A.I.

FGBU "Federal'nyĭ meditsinskiĭ biofizicheskiĭ tsentr im. A.I. Burnaziana" FMBA Rossii, Moskva

Zabezhinskiyi D.A.

State scientific center, Federal medical biophysical center named after A.I. Burnasyan, Federal medico-biological agency, Moscow, Russia

Naidyonov E.V.

State Research Center of the Russian Federation - Burnazyan Federal Medical Biophysical Center, FMBA of Russia, Moscow, Russia

Bashkov A.N.

State scientific center, Federal medical biophysical center named after A.I. Burnasyan, Federal medico-biological agency, Moscow, Russia

Chuchuev E.S.

Khirurgicheskoe otdelenie opukholeĭ pecheni i podzheludochnoĭ zhelezy Rossiĭskogo onkologicheskogo nauchnogo tsentra im. N.N. Blokhina RAMN, Moskva

Shabalin M.V.

State scientific center, Federal medical biophysical center named after A.I. Burnasyan, Federal medico-biological agency, Moscow, Russia

Syutkin V.E.

State Research Center — Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency of Russia, Moscow, Russia

Salvage liver transplantation for hepatocellular carcinoma

Authors:

Voskanyan S.Ae., Sushkov A.I., Artem'ev A.I., Zabezhinskiyi D.A., Naidyonov E.V., Bashkov A.N., Chuchuev E.S., Shabalin M.V., Syutkin V.E.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2019;(10): 21‑28

DOI: 10.17116/hirurgia201910121

Read: 2818 times

Download PDF (RU)
Contact the author
Table of contents

SALVAGE LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA
SALVAGE LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA

To cite this article:

Voskanyan SAe, Sushkov AI, Artem'ev AI, et al. . Salvage liver transplantation for hepatocellular carcinoma. Pirogov Russian Journal of Surgery. 2019;(10):21‑28. (In Russ.)
https://doi.org/10.17116/hirurgia201910121

Подписка 2026 Хирургия. Журнал им. Н.И. Пирогова (Pirogov Russian Journal of Surgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Prognostic factors and preoperative therapy in rese­ctable intrahepatic cholangiocarcinoma. Piro­gov Russian Journal of Surgery. 2025;(1):5-13
Lapa­roscopic ALPPS procedure: a series of cases. Piro­gov Russian Journal of Surgery. 2025;(2):20-26
Textbook outcome for liver rese­ction. Survey of respondents in national centers. Piro­gov Russian Journal of Surgery. 2025;(4):5-11
Primary outcomes after major anatomical liver rese­ctions in infa­nts at the National Children’s Medi­cal Center. Piro­gov Russian Journal of Surgery. 2025;(4):86-94
Mini­mally inva­sive surgery for liver echi­nococcosis. Piro­gov Russian Journal of Surgery. 2025;(9):61-68
Hepa­tic hema­ngioma: what surgeons need to know. Piro­gov Russian Journal of Surgery. 2025;(11):102-108
Hepa­tocellular carcinoma asso­ciated with nona­lcoholic fatty liver disease. P.A. Herzen Journal of Onco­logy. 2024;(6):57-62
Expe­rience of 100 lapa­roscopic liver rese­ctions in an onco­logy hospital. P.A. Herzen Journal of Onco­logy. 2025;(4):7-13
Abstract:

Objective — to analyze clinical course and the results of salvage liver transplantation in patients with recurrent hepatocellular carcinoma (HCC) after liver resection. Material and methods. A 54-year-old man with HCV-infection and HCC and 22-year-old woman with fibrolamellar variant of HCC underwent resection of the right and left liver lobe, respectively. The first patient experienced recurrent HCC four times with an interval of 3—6 months within 2 years after surgery. Repeated liver resection was made in first three cases, right liver lobe transplantation — after the fourth recurrence. In the second patient, HCC recurred in 4 months after resection and was accompanied by subtotal portal vein thrombosis. Therefore, repeated liver resection was excluded and patient underwent right liver lobe transplantation. Results. Patients are alive in 5 and 3.5 years after liver resection and in 2.5 and 3 years after transplantation, respectively. There are currently no signs of recurrent HCC in the graft.

Keywords:

hepatocellular carcinoma
liver resection
liver transplantation
salvage transplantation

Authors:

Voskanyan S.Ae.

State scientific center, Federal medical biophysical center named after A.I. Burnasyan, Federal medico-biological agency, Moscow, Russia

Sushkov A.I.

State Research Center — Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency of Russia, Moscow, Russia

Artem'ev A.I.

FGBU "Federal'nyĭ meditsinskiĭ biofizicheskiĭ tsentr im. A.I. Burnaziana" FMBA Rossii, Moskva

Zabezhinskiyi D.A.

State scientific center, Federal medical biophysical center named after A.I. Burnasyan, Federal medico-biological agency, Moscow, Russia

Naidyonov E.V.

State Research Center of the Russian Federation - Burnazyan Federal Medical Biophysical Center, FMBA of Russia, Moscow, Russia

Bashkov A.N.

State scientific center, Federal medical biophysical center named after A.I. Burnasyan, Federal medico-biological agency, Moscow, Russia

Chuchuev E.S.

Khirurgicheskoe otdelenie opukholeĭ pecheni i podzheludochnoĭ zhelezy Rossiĭskogo onkologicheskogo nauchnogo tsentra im. N.N. Blokhina RAMN, Moskva

Shabalin M.V.

State scientific center, Federal medical biophysical center named after A.I. Burnasyan, Federal medico-biological agency, Moscow, Russia

Syutkin V.E.

State Research Center — Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency of Russia, Moscow, Russia

Close metadata

References:

  1. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends — An Update. Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27. https://doi.org/10.1158/1055-9965.EPI-15-0578
  2. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013 Jul;47:S2-S6. https://doi.org/10.1097/MCG.0b013e3182872f29
  3. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology. 2006 Jun;43(6):1303-1310. https://doi.org/10.1002/hep.21176
  4. Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2007 Aug;5(8):938-945. https://doi.org/10.1016/j.cgh.2007.02.039
  5. Giannini EG, Marenco S, Bruzzone L, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F. Hepatocellular carcinoma in patients without cirrhosis in Italy. Dig Liver Dis. 2013 Feb;45(2):164-169. https://doi.org/10.1016/j.dld.2012.08.018
  6. Gaddikeri S, McNeeley MF, Wang CL, Bhargava P, Dighe MK, Yeh MM, Dubinsky TJ, Kolokythas O, Lalwani N. Hepatocellular carcinoma in the noncirrhotic liver. AJR Am J Roentgenol. 2014 Jul;203(1): W34-W47. https://doi.org/10.2214/AJR.13.11511
  7. European Association for The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012 Apr;56(4):908-943. https://doi.org/10.1016/j.jhep.2011.12.001
  8. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008 May 21;100(10):698-711. https://doi.org/10.1093/jnci/djn134
  9. Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis. 2010 May;42(5):341-347. https://doi.org/10.1016/j.dld.2009.09.002
  10. Lerut J, Mergental H, Kahn D, Albuquerque L, Marrero J, Vauthey JN, Porte RJ. Place of liver transplantation in the treatment of hepatocellular carcinoma in the normal liver. Liver Transpl. 2011 Oct;17 Suppl 2:S90-S97. https://doi.org/10.1002/lt.22393
  11. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996 Mar 14;334(11):693-699.
  12. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001 Jun;33(6):1394-1403.
  13. Herrero JI, Sangro B, Quiroga J, Pardo F, Herraiz M, Cienfuegos JA, Prieto J. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl. 2001 Jul;7(7):631-636.
  14. Silva M, Moya A, Berenguer M, Sanjuan F, López-Andujar R, Pareja E, Torres-Quevedo R, Aguilera V, Montalva E, De Juan M, Mattos A, Prieto M, Mir J. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl. 2008 Oct;14(10):1449-1460. https://doi.org/10.1002/lt.21576
  15. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, Liang TB, Wu LM. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008 Jun 27;85(12):1726-1732. https://doi.org/10.1097/TP.0b013e31816b67e4
  16. Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW. Bridging and down staging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol. 2013 Nov 21;19(43):7515-7530. https://doi.org/10.3748/wjg.v19.i43.7515
  17. Majno PE, Sarasin FP, Mentha G, Hadengue A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. Hepatology. 2000 Apr;31(4):899-906.
  18. Li HY, Wei YG, Yan LN, Li B. Salvage liver transplantation in the treatment of hepatocellular carcinoma: a metaanalysis. World J Gastroenterol. 2012 May 21;18(19):2415-2422. https://doi.org/10.3748/wjg.v18.i19.2415
  19. Zhu Y, Dong J, Wang WL, Li MX, Lu Y. Short- and long-term outcomes after salvage liver transplantation versus primary liver transplantation for hepatocellular carcinoma: a meta-analysis. Transplant Proc. 2013 Nov;45(9):3329-3342. https://doi.org/10.1016/j.transproceed.2013.06.004
  20. Xiong Q, Geng TT, He L, Gao H. Harm and Benefits of Salvage Transplantation for Hepatocellular Carcinoma: An Updated Metaanalysis. Transplant Proc. 2016 Dec;48(10):3336-3347. https://doi.org/10.1016/j.transproceed.2016.09.047
  21. Abecassis MM, Fisher RA, Olthoff KM, Freise CE, Rodrigo DR, Samstein B, Kam I, Merion RM; A2ALL Study Group. Complications of living donor hepatic lobectomy — a comprehensive report. Am J Transplant. 2012 May;12(5):1208-1217. https://doi.org/10.1111/j.1600-6143.2011.03972.x
  22. Cholongitas E, Mamou C, Rodríguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int. 2014 Oct;27(10):1039-1049. https://doi.org/10.1111/tri.12372
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.